鲁斯可皂苷元的药理活性机制研究进展-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

鲁斯可皂苷元的药理活性机制研究进展

Research progress on pharmacological activity mechanism of Ruscogenin

ES评分 0 浏览量：1045 下载量：0

DOI	10.12208/j.ijcr.20240133
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2024, 8(4)
作者	张锦峰,张剑,余伯阳*,
作者单位	中国药科大学中药学院中药可追溯与标准化研究中心江苏南京中国药科大学中药学院中药可追溯与标准化研究中心江苏南京 ;
摘要	麦冬作为一种滋阴药，在传统中药中占有重要地位。作为麦冬皂苷中的主要苷元，鲁斯可皂苷元具有明显的抗心血管疾病、急性肺损伤、预防血脑屏障功能障碍、抗肿瘤、抗炎等多种药理活性。本文重点综述近年来有关鲁斯可皂苷元药理活性机制的研究进展，着重介绍抗心脑血管疾病、改善学习记忆障碍、抗肿瘤、抗炎、免疫调节、改善肝肺病理性损伤等药理作用，以期为今后对鲁斯可皂苷元的深入研究和开发利用提供参考。
Abstract	Ophiopogon, as a Yin nourishing medicine, plays an important role in traditional Chinese medicine. As the main aglycone in ophiopogon saponins, Ruscogenin has obvious pharmacological activities such as anti-cardiovascular disease, acute lung injury, prevention of blood-brain barrier dysfunction, anti-tumor, anti-inflammatory and so on. In this paper, the research progress of pharmacological activity mechanism of Luscogenin in recent years was reviewed, and the pharmacological effects of anti-cardiovascular and cerebrovascular diseases, improvement of learning and memory disorders, anti-tumor, anti-inflammatory, immunomodulatory, and improvement of rational injury of liver and lung disease were introduced, so as to provide reference for further research, development and utilization of Luscogenin in the future.
关键词	鲁斯可皂苷元；药理活性；作用机制
KeyWord	Ruscogenin; Pharmacological activity; Action mechanisms
基金项目
页码	5-8

参考文献
相关文献

[1] Masullo, M., C. Pizza, and S. Piacente, Ruscus Genus: A Rich Source of Bioactive Steroidal Saponins. Planta Medica, 2016. 82(18): p. 1513-1524.

[2] Fu, F., et al., Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2. Antioxidants, 2022. 11(3).

[3] Lai, Q., et al., Inhibition of OAT1/3 and CMPF uptake attenuates myocardial ischemia-induced chronic heart failure via decreasing fatty acid oxidation and the therapeutic effects of ruscogenin. Translational Research, 2023. 261: p. 1-15.

[4] Guan, T., et al., Ruscogenin reduces cerebral ischemic injury via NF-κB-mediated inflammatory pathway in the mouse model of experimental stroke. European Journal of Pharmacology, 2013. 714(1-3): p. 303-311.

[5] Cao, G., et al., Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. International Journal of Molecular Sciences, 2016. 17(9).

[6] Zhang, S., et al., Ruscogenin timing administration mitigates cerebral ischemia-reperfusion injury through regulating circadian genes and activating Nrf2 pathway. Phytomedicine, 2023. 120.

[7] Song, J., et al., Ruscogenin Mainly Inhibits Nuclear Factor-κB but Not Akt and Mitogen-Activated Protein Kinase Signaling Pathways in Human Umbilical Vein Endothelial Cells. Journal of Pharmacological Sciences, 2010. 113(4): p. 409-413.

[8] Wu, Y., et al., Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by suppressing TLR4 signaling. Biomed Pharmacother, 2020. 125: p. 109868.

[9] Wang, Y., et al., Ruscogenin attenuates sepsis-induced acute lung injury and pulmonary endothelial barrier dysfunction via TLR4/Src/p120-catenin/VE-cadherin signalling pathway. J Pharm Pharmacol, 2021. 73(7): p. 893-900.

[10] Wu, Y., et al., Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling. Acta Pharm Sin B, 2022. 12(3): p. 1198-1212.

[11] Pan, D., et al., Ruscogenin Attenuates Lipopolysaccharide-Induced Septic Vascular Endothelial Dysfunction by Modulating the miR-146a-5p/NRP2/SSH1 Axis. Drug Des Devel Ther, 2022. 16: p. 1099-1106.

[12] Huang, J., et al., Ruscogenin ameliorates dasatinib-induced intestinal barrier dysfunction via ErbB4/YAP and ROCK/MLC pathways. J Nat Med, 2023. 77(4): p. 735-747.

[13] Liang, X., et al., Ruscogenin alleviates cognitive dysfunction by inhibiting the activation of isoflurane-induced NLRP3 inflammasome in aged mice. Quality Assurance and Safety of Crops & Foods, 2021. 13(3): p. 109-115.

[14] Shi, K. and B. Wang, Ruscogenin regulates endogenous antioxidation in dopamine neurons by activating Keap1/Nrf2/HO-1 pathway. Tropical Journal of Pharmaceutical Research, 2023. 22(9): p. 1779-1784.

[15] Hua, H., Y. Zhu, and Y.-H. Song, Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway. Biomedicine & Pharmacotherapy, 2018. 101: p. 115-122.

[16] Lv, Y., et al., Ruscogenin attenuated tight junction injury and tumor migration in colorectal liver metastasis mice via regulating TRAP1. Translational Cancer Research, 2021. 10(3): p. 1470-1483.

[17] Zhao, J., et al., Anticancer Effect of Ruscogenin in B(a)P-Induced Lung Cancer in Mice via Modulation of Proinflammatory Cytokines and Mitochondrial Enzymes. Applied Biochemistry and Biotechnology, 2022. 194(12): p. 5862-5877.

[18] Huang, Y.-L., et al., Possible Mechanism of the Anti-inflammatory Activity of Ruscogenin: Role of Intercellular Adhesion Molecule-1 and Nuclear Factor-κB. Journal of Pharmacological Sciences, 2008. 108(2): p. 198-205.

[19] Lin, Y.N., et al., Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway. The Journal of Steroid Biochemistry and Molecular Biology, 2015. 154: p. 85-93.

[20] Liu, H., et al., Ruscogenin alleviates palmitic acid-induced endothelial cell inflammation by suppressing TXNIP/NLRP3 pathway. Tropical Journal of Pharmaceutical Research, 2020. 19(8): p. 1605-1610.

[21] Wen, H., et al., Ruscogenins Improve CD-Like Enteritis by Inhibiting Apoptosis of Intestinal Epithelial Cells and Activating Nrf2/NQO1 Pathway. Oxidative Medicine and Cellular Longevity, 2022. 2022: p. 1-12.

引用本文

张锦峰,张剑,余伯阳*. 鲁斯可皂苷元的药理活性机制研究进展 [J]. 国际临床研究杂志. 2024; 8; (4). 5 - 8.

文献评论

相关学者

相关机构